Mater Misericordiae University Hospital — Clinical Trial Site

114 Registered trials

50 Currently recruiting

Organisation

Mater Misericordiae University Hospital

Location

Dublin 7, Ireland

Identifier

ORG-100028391

Address

Eccles Street, Ireland

Departments

#192: Pulmonology
3901: Haematology
3901: Oncology
3901: START Dublin
3902:Clinical Trials Research Unit
Cancer Directorate Radiation Oncology
Cardiology
Cardiovascular Research Institute
Catherine McAuley Centre
Catherine McAuley Research Centre
Clinical Trials Research Unit
Clinical Trials Unit
Department of Infectious Diseases
Department of Medical Oncology
Department of Oncology
Department of Radiation Oncology
Dept Of ID
Dermatology
Gynaecologic Oncology
Gynaecological Oncology
Haematologist
Haematology
Haematology/Oncology Clinical Trial Research Unit
Hematology
Infectious Disease
Infectious Diseases
Institute For Cancer Research
Intensive Care Unit
Medical Oncology
n/a
NA
Neurology
Neurology / Stroke
nfectious diseases and genitourinary medicine
Oncology
Oncology Department
Oncology/Haematology Clinical Trials Research Unit
Pain Medicine
Pathology
Respiratory
Respiratory Department
Respiratory Medicine
START Dublin
Stroke Dept
Trials Unit

Clinical trials at this site (114)

Search interface

A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting

2023-504807-94-00 Breast Cancer; Advanced solid tumors including but not 7 2023-12-26
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Resectable, Early-stage (II to IIIB) Non-small Cell Lun 4 2022-06-10
A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight … Recruiting

2024-513168-24-00 HIV & Obesity 4 2022-06-01
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
EPO-TRAUMA Recruiting

2023-506081-31-00 Traumatic Injury 5 2022-03-29
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr… Ended

2024-511754-41-00 idiopathic pulmonary fibrosis 4 2025-05-29
First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended

2023-506842-22-00 Recurrent endometrial cancer, recurrent epithelial ovar 7 2025-05-19
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Recurrent Ovarian Cancer with High Folate Receptor-Alph 4 2024-11-05
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arte… Ended

2023-506334-75-00 Pulmonary Arterial Hypertension 5 2024-07-12
Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and surv… Ended

2024-511306-23-00 Breast cancer, colon cancer, rectal cancer, stomach can 5 2024-07-01
Vaccination to prevent Mpox Infection (MPOX-VAX Study) Ended

2023-507881-19-00 Mpox infection 6 2024-06-29
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Endometrial cancer 5 2024-03-08
A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended

2023-504993-40-00 Human immunodeficiency virus (HIV) 5 2024-02-14
PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer … Ended

2024-513429-21-00 Metastatic refractory Pancreatic Cancer 4 2023-06-27
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended

2023-505579-53-00 Diffuse large B-cell lymphoma (DLBCL) 5 2022-10-25
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima… Ended

2024-512749-18-00 Newly diagnosed Multiple Myeloma 4 2022-03-03